EGFR and non-small cell lung carcinoma: Mainly due to crossover, a benefit of EGFR-TKI therapy in EGFR-positive NSCLC on overall survival (OS) is hard to demonstrate in the context of prospective randomized trials [20, 21, 22, 23].